← Back to Search

Integrin Antagonist

Bexotegrast for Idiopathic Pulmonary Fibrosis

Phase 2
Recruiting
Research Sponsored by Pliant Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥ 40 years of age prior to screening
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 54 weeks
Awards & highlights

Study Summary

This trial tests a new drug to see if it helps people with a lung condition called idiopathic pulmonary fibrosis.

Who is the study for?
This trial is for adults over 40 with idiopathic pulmonary fibrosis diagnosed within the last 7 years, having certain lung function levels. Stable patients on IPF treatments or those not treated for at least 8 weeks can join. Exclusions include smokers, liver/kidney disease sufferers, recent cancer patients (except some skin/cervical cancers), pregnant/breastfeeding women, and those on unapproved fibrosis drugs.Check my eligibility
What is being tested?
The BEACON-IPF study tests bexotegrast (PLN-74809) against a placebo to see if it's safe and effective for treating idiopathic pulmonary fibrosis. Participants are randomly assigned to receive either the drug or a placebo without knowing which one they're getting.See study design
What are the potential side effects?
While specific side effects of bexotegrast aren't listed here, common ones in trials may include gastrointestinal issues, headaches, dizziness, potential liver enzyme changes, and fatigue. The exact side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 40 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 54 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 54 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in absolute FVC (mL)
Secondary outcome measures
Absolute change from baseline in quantitative lung fibrosis (QLF) extent (%)
Change from baseline in King's Brief Interstitial Lung Disease (K-BILD) questionnaire Total score
Change from baseline in Living with Pulmonary Fibrosis (L-PF) Dyspnoea and Cough Domain score
+6 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: PlaceboExperimental Treatment1 Intervention
Placebo
Group II: Bexotegrast (PLN-74809) 320 mg DoseExperimental Treatment1 Intervention
Bexotegrast (PLN-74809) 320 mg Dose - 52 weeks
Group III: Bexotegrast (PLN-74809) 160 mg DoseExperimental Treatment1 Intervention
Bexotegrast (PLN-74809) 160 mg Dose - 52 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PLN-74809
2020
Completed Phase 2
~260
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

Pliant Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
373 Total Patients Enrolled
4 Trials studying Idiopathic Pulmonary Fibrosis
169 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Pliant Therapeutics Medical MonitorStudy DirectorPliant Therapeutics, Inc.
4 Previous Clinical Trials
327 Total Patients Enrolled
2 Trials studying Idiopathic Pulmonary Fibrosis
129 Patients Enrolled for Idiopathic Pulmonary Fibrosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is access to this research still available to potential participants?

"The clinical trial, which was initially published on October 15th 2023, is actively seeking participants and has recently been updated as of the 18th. This can be verified online via clinicaltrials.gov."

Answered by AI

How many participants are undergoing treatment in the current research project?

"The clinical trial necessitates the recruitment of 267 patients who meet specific eligibility criteria. Those eager to partake can join at Clinical Site Partners - Leesburg, based in Leesburg, Florida or IU Health Advanced Heart and Lung Care located in Indianapolis, Indiana."

Answered by AI

How many sites are currently participating in this research endeavor?

"Patients for this clinical trial are being accepted at Clinical Site Partners - Leesburg in Florida, IU Health Advanced Heart and Lung Care in Indianapolis, as well as Creighton University in Omaha. Additionally, 16 other medical centres across the United States are also participating."

Answered by AI

Would taking PLN-74809 at a 160 mg dosage present any health risks?

"Although data on the efficacy of Bexotegrast (PLN-74809) 160 mg Dose is lacking, there are some indications that it may be safe, thus we placed a score of 2."

Answered by AI

Who else is applying?

What site did they apply to?
Clinical Site Partners - Leesburg
University of Utah
Vanderbilt University Medical Center
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

Why did patients apply to this trial?

Recently diagnosed with IPF and researched medications with favorable outcomes. I plan on starting pirfenidone in late December.
PatientReceived no prior treatments
I'd like to live a little longer, however my wife's new insurance carrier will not provide either OFEV, Espriet, or their generic equivalents. at a reasonable price I can afford.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

How many visits are required?
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
2023. "Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06097260.
All > Kansas City > Knoxville
~240 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top